Alzheimer's Society comment on new research suggesting tarenflurbil may be effective in halting symptoms of Alzheimer's disease, from the Lancet Neurology

A drug that slows the effects of this devastating disease would provide hope to thousands who are diagnosed each year. Two more clinical trials of this drug are currently underway and we eagerly look forward to the results of these studies next year.

Prof Clive Ballard
Director of Research
Alzheimer's Society

Reference

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial, http://neurology.thelancet.com/, (Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, Kenton H Zavitz, Edward A Swabb, Mark A Laughlin, on behalf of the Tarenflurbil Phase II Study investigators).

Notes to editors

Information about Alzheimer's Society
Alzheimer's Society is the leading care and research charity for people with all forms dementia and their carers. It provides information and education, support for carers, and quality day and home care. It funds medical and scientific research and campaigns for improved health and social services and greater public understanding of dementia.

The Alzheimer's Society provides a national help line on 0845 3000 336 and website http://www.alzheimers.org.uk/. Please include this information in any publication that uses these comments.

For more information contact: Press Office 0207 423 3595 press@alzheimers.org.uk